Edgardo Kaplinsky. (2020). DAPA-HF trial: Dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. BioExcel Publishing Ltd.
Chicago Style (17th ed.) CitationEdgardo Kaplinsky. DAPA-HF Trial: Dapagliflozin Evolves from a Glucose-lowering Agent to a Therapy for Heart Failure. BioExcel Publishing Ltd, 2020.
MLA (9th ed.) CitationEdgardo Kaplinsky. DAPA-HF Trial: Dapagliflozin Evolves from a Glucose-lowering Agent to a Therapy for Heart Failure. BioExcel Publishing Ltd, 2020.
Warning: These citations may not always be 100% accurate.